Cite
HARVARD Citation
Wang, G. et al. (2022). Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Alzheimer's & dementia. 14 (1), p. n/a. [Online].